Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 3.14 MB
Add to list
  1. Search results
  2. Strategies to manage hepatitis C viru...

Strategies to manage hepatitis C virus (HCV) disease burden

H Wedemeyer, AS Duberg, M Buti, WM Rosenberg, S Frankova, G Esmat, N Örmeci, Hans Van Vlierberghe (UGent) , M Gschwantler, U Akarca, et al.
(2014) JOURNAL OF VIRAL HEPATITIS. 21(suppl. 1). p.60-89
Author
Organization
Abstract
The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
Keywords
diagnosis, epidemiology, GENOTYPE 1 INFECTION, disease burden, hepatitis C, DRUG-USERS, RISK-FACTORS, UNITED-STATES, TRIPLE THERAPY, RANDOMIZED-TRIAL, HEPATOCELLULAR-CARCINOMA, PEGINTERFERON ALPHA-2B, SINGLE-SOURCE OUTBREAK, SUSTAINED VIROLOGICAL RESPONSE, incidence, prevalence, treatment, scenarios, mortality, HCV

Downloads

  • Download
    (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 3.14 MB

Citation

Please use this url to cite or link to this publication:

MLA
Wedemeyer, H., et al. “Strategies to Manage Hepatitis C Virus (HCV) Disease Burden.” JOURNAL OF VIRAL HEPATITIS, vol. 21, no. suppl. 1, 2014, pp. 60–89, doi:10.1111/jvh.12249.
APA
Wedemeyer, H., Duberg, A., Buti, M., Rosenberg, W., Frankova, S., Esmat, G., … Gower, E. (2014). Strategies to manage hepatitis C virus (HCV) disease burden. JOURNAL OF VIRAL HEPATITIS, 21(suppl. 1), 60–89. https://doi.org/10.1111/jvh.12249
Chicago author-date
Wedemeyer, H, AS Duberg, M Buti, WM Rosenberg, S Frankova, G Esmat, N Örmeci, et al. 2014. “Strategies to Manage Hepatitis C Virus (HCV) Disease Burden.” JOURNAL OF VIRAL HEPATITIS 21 (suppl. 1): 60–89. https://doi.org/10.1111/jvh.12249.
Chicago author-date (all authors)
Wedemeyer, H, AS Duberg, M Buti, WM Rosenberg, S Frankova, G Esmat, N Örmeci, Hans Van Vlierberghe, M Gschwantler, U Akarca, S Aleman, I Balik, T Berg, F Bihl, M Bilodeau, AJ Blasco, CE Brandão Mello, P Bruggmann, F Calinas, JL Calleja, H Cheinquer, PB Christensen, M Clausen, HSM Coelho, M Cornberg, ME Cramp, GJ Dore, W Doss, MH El-Sayed, G Ergör, C Estes, K Falconer, J Félix, MLG Ferraz, PR Ferreira, J García-Samaniego, J Gerstoft, JA Giria, FL Goncales, M Guimarães Pessôa, C Hézode, SJ Hindman, H Hofer, P Husa, R Idilman, M Kåberg, KDE Kaita, A Kautz, S Kaymakoglu, M Krajden, H Krarup, W Laleman, D Lavanchy, P Lázaro, RT Marinho, P Marotta, S Mauss, MCM Correa, C Moreno, B Müllhaupt, RP Myers, V Nemecek, ALH Øvrehus, J Parkes, KM Peltekian, A Ramji, H Razavi, N Reis, SK Roberts, F Roudot-Thoraval, SD Ryder, R Sarmento-Castro, C Sarrazin, D Semela, M Sherman, GE Shiha, J Sperl, P Stärkel, RE Stauber, AJ Thompson, P Urbanek, P Van Damme, I van Thiel, Dominique Vandijck, W Vogel, I Waked, N Weis, J Wiegand, A Yosry, A Zekry, F Negro, W Sievert, and E Gower. 2014. “Strategies to Manage Hepatitis C Virus (HCV) Disease Burden.” JOURNAL OF VIRAL HEPATITIS 21 (suppl. 1): 60–89. doi:10.1111/jvh.12249.
Vancouver
1.
Wedemeyer H, Duberg A, Buti M, Rosenberg W, Frankova S, Esmat G, et al. Strategies to manage hepatitis C virus (HCV) disease burden. JOURNAL OF VIRAL HEPATITIS. 2014;21(suppl. 1):60–89.
IEEE
[1]
H. Wedemeyer et al., “Strategies to manage hepatitis C virus (HCV) disease burden,” JOURNAL OF VIRAL HEPATITIS, vol. 21, no. suppl. 1, pp. 60–89, 2014.
@article{4380202,
  abstract     = {{The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.}},
  author       = {{Wedemeyer, H and Duberg, AS and Buti, M and Rosenberg, WM and Frankova, S and Esmat, G and Örmeci, N and Van Vlierberghe, Hans and Gschwantler, M and Akarca, U and Aleman, S and Balik, I and Berg, T and Bihl, F and Bilodeau, M and Blasco, AJ and Brandão Mello, CE and Bruggmann, P and Calinas, F and Calleja, JL and Cheinquer, H and Christensen, PB and Clausen, M and Coelho, HSM and Cornberg, M and Cramp, ME and Dore, GJ and Doss, W and El-Sayed, MH and Ergör, G and Estes, C and Falconer, K and Félix, J and Ferraz, MLG and Ferreira, PR and García-Samaniego, J and Gerstoft, J and Giria, JA and Goncales, FL and Guimarães Pessôa, M and Hézode, C and Hindman, SJ and Hofer, H and Husa, P and Idilman, R and Kåberg, M and Kaita, KDE and Kautz, A and Kaymakoglu, S and Krajden, M and Krarup, H and Laleman, W and Lavanchy, D and Lázaro, P and Marinho, RT and Marotta, P and Mauss, S and Correa, MCM and Moreno, C and Müllhaupt, B and Myers, RP and Nemecek, V and Øvrehus, ALH and Parkes, J and Peltekian, KM and Ramji, A and Razavi, H and Reis, N and Roberts, SK and Roudot-Thoraval, F and Ryder, SD and Sarmento-Castro, R and Sarrazin, C and Semela, D and Sherman, M and Shiha, GE and Sperl, J and Stärkel, P and Stauber, RE and Thompson, AJ and Urbanek, P and Van Damme, P and van Thiel, I and Vandijck, Dominique and Vogel, W and Waked, I and Weis, N and Wiegand, J and Yosry, A and Zekry, A and Negro, F and Sievert, W and Gower, E}},
  issn         = {{1352-0504}},
  journal      = {{JOURNAL OF VIRAL HEPATITIS}},
  keywords     = {{diagnosis,epidemiology,GENOTYPE 1 INFECTION,disease burden,hepatitis C,DRUG-USERS,RISK-FACTORS,UNITED-STATES,TRIPLE THERAPY,RANDOMIZED-TRIAL,HEPATOCELLULAR-CARCINOMA,PEGINTERFERON ALPHA-2B,SINGLE-SOURCE OUTBREAK,SUSTAINED VIROLOGICAL RESPONSE,incidence,prevalence,treatment,scenarios,mortality,HCV}},
  language     = {{eng}},
  number       = {{suppl. 1}},
  pages        = {{60--89}},
  title        = {{Strategies to manage hepatitis C virus (HCV) disease burden}},
  url          = {{http://doi.org/10.1111/jvh.12249}},
  volume       = {{21}},
  year         = {{2014}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: